Thursday, August 28, 2014 5:43:33 PM
Thanks to you and many others for correcting the misinformation regarding NNVC.
drkazmd65 Thursday, 08/28/14 11:48:45 AM
Re: Rawnoc post# 97677
Post # of 97708
As I said,.... The company (since many hypotheses that it has tested along the way are supported by the data) actually has 9+ years demonstrating almost exactly the opposite of failure. They have just not (yet) completed the final few steps needed to get a revenue stream going.
That'll happen soon enough.
Show us evidence that Dr. Diwan has made a 'pofit' in fronting the money to build the new Shelton, CT facility, and then selling it back to the company,....
Other than innuendo - there has been no such evidence submitted that can be vetted. The assumption that Dr. Diwan has scammed NNVC shareholders to his own benefit in doing this is merely conjecture. Show us some evidence to the contrary,....
The premise you make in this question of "doesn't the Dr. know when there will be enough Flucide for BASi" is a false one in that Dr. Seymour may (indeed) know when it is that we are likely to have enough Flucide to send it off to BASi,.... The company is under no obligation under SEC rules in telling 'us' what the specific timeline or expectation is. In fact - doing so could be viewed as an attempt to manipulate (positively or negatively) market perception of the stock prematurely.
Just because 'we' out here in the peanut gallery haven't been told what the timeline expectations are does not mean that the Company doesn't know.
What is going on pretty much does the opposite of 'defy logic and common sense'.
Send illegal stock manipulators to:https://denebleo.sec.gov/TCRExternal/index.xhtml
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM